EVAX News

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop

Evaxion receives Prix Galien UK Award for Best digital health solution

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Evaxion announces business update and first quarter 2026 financial results

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial